62.3 Adult & Pediatric Attention-Deficit/Hyperactivity Disorder

Explicit Curriculum Focus: Attention-Deficit/Hyperactivity Disorder (Appendix A CC_167)

Attention-Deficit/Hyperactivity Disorder (ADHD) is a chronic, highly heritable neurodevelopmental disorder characterized by developmentally inappropriate levels of inattention, hyperactivity, and impulsivity. Affecting approximately 8% to 10% of school-aged children and adolescents, ADHD was historically misconceptualized as a self-limiting childhood behavioral problem. Longitudinal epidemiological studies demonstrate that ADHD persists into adulthood in 50% to 60% of individuals, affecting approximately 4% to 5% of the adult workforce. In adulthood, untreated ADHD is associated with severe occupational instability, relationship breakdown, financial delinquency, substance use disorders, motor vehicle collisions, and elevated all-cause mortality.

                  FRONTO-SUBCORTICAL DYSREGULATION IN ADHD

     Genetic Polymorphisms (DAT1, DRD4, NET) & Environmental Neurodevelopmental Risks
                                       │
                                       ▼
        Hypoactive Catecholaminergic Tone in Prefrontal-Striatal Networks
                                       │
        ┌──────────────────────────────┴──────────────────────────────┐
        ▼                                                             ▼
Prefrontal Norepinephrine (NE) Deficiency                  Prefrontal Dopamine (DA) Deficiency
 • Decreased stimulation of postsynaptic                   • Decreased stimulation of postsynaptic
   alpha-2A adrenergic receptors                             dopamine D1 receptors
 • Weakened signal transmission in working memory          • Increased background noise and distractibility
 • Inability to sustain attention & focus                  • Impaired behavioral inhibition & impulsivity
                                       │
                                       ▼
         Executive Dysfunction, Emotional Dysregulation, & Working Memory Deficits

Neurobiology: The Catecholamine Signal-to-Noise Paradigm

Functional neuroimaging and molecular pharmacology demonstrate that ADHD is driven by structural and functional hypoactivity within the prefrontal cortex (PFC), anterior cingulate cortex, and striatum (caudate and putamen). The PFC governs executive functions: sustaining attention, organizing tasks, suppressing extraneous environmental distractions, delaying gratification, and regulating emotional responses.

• Alpha-2A Receptors Enhance the "Signal": Postsynaptic $\alpha_{2A}$-adrenergic receptors in prefrontal dendritic spines strengthen relevant neuronal network connections, enhancing the signal of the task at hand and sustaining working memory.
• Dopamine D1 Receptors Dampen the "Noise": Postsynaptic dopamine D1 receptors decrease inappropriate, irrelevant synaptic inputs, effectively suppressing extraneous background noise.
• Pathological Catecholamine Depletion: In patients with ADHD, excessive clearance of synaptic dopamine by the dopamine transporter (DAT) and norepinephrine by the norepinephrine transporter (NET) leaves the prefrontal cortex catecholamine-deficient. This degrades the signal-to-noise ratio, rendering the brain unable to prioritize tasks, resist impulses, or sustain mental effort.

---

DSM-5-TR Diagnostic Criteria for ADHD

Under DSM-5-TR, establishing a diagnosis of ADHD requires a comprehensive evaluation demonstrating a persistent pattern of inattention and/or hyperactivity-impulsivity that interferes with functioning or development, as characterized by Domain 1 (Inattention) and/or Domain 2 (Hyperactivity and Impulsivity).

                    DSM-5 SYMPTOM THRESHOLDS FOR ADHD

   Age Category                       Threshold for Diagnosis (Per Domain)
   ═════════════════════════════════════════════════════════════════════════════════════════════════════════════
   Children (< 17 years)              At least 6 of 9 symptoms present for at least 6 consecutive months
   Adolescents & Adults (>= 17 years) At least 5 of 9 symptoms present for at least 6 consecutive months
   ═════════════════════════════════════════════════════════════════════════════════════════════════════════════

                    THE NINE INATTENTION SYMPTOMS (DOMAIN 1)

   1. Careless Mistakes: Fails to give close attention to details or makes careless mistakes in schoolwork,
      work duties, or other activities.
   2. Sustaining Attention: Often has difficulty sustaining attention in tasks or play activities (lectures,
      lengthy reading, conversations).
   3. Appears Not to Listen: Often does not seem to listen when spoken to directly (mind seems elsewhere).
   4. Incomplete Follow-Through: Often fails to follow through on instructions and fails to finish schoolwork,
      chores, or workplace obligations.
   5. Disorganization: Often has difficulty organizing tasks and activities (poor time management, messy work,
      misses deadlines).
   6. Avoids Sustained Mental Effort: Avoids, dislikes, or is reluctant to engage in tasks requiring sustained
      cognitive effort (reports, forms).
   7. Loses Essential Items: Frequently loses materials necessary for tasks (school assignments, eyeglasses,
      keys, wallet, phone).
   8. Easily Distracted: Easily distracted by extraneous stimuli (or unrelated intrusive thoughts in adults).
   9. Forgetful in Daily Activities: Forgetful in daily routines (chores, running errands, returning calls,
      paying bills, appointments).

              THE NINE HYPERACTIVITY & IMPULSIVITY SYMPTOMS (DOMAIN 2)

   1. Fidgets / Squirms: Often fidgets with or taps hands or feet, or squirms uncomfortably in seat.
   2. Leaves Seat: Leaves seat in situations when remaining seated is expected (classroom, office, dinner table).
   3. Inappropriate Running/Climbing: Runs about or climbs in situations where it is inappropriate (in adults,
      limited to subjective restlessness).
   4. Unable to Play Quietly: Often unable to play or engage in leisure activities quietly.
   5. "Driven by a Motor": Often "on the go," acting as if driven by an internal motor; uncomfortable being still.
   6. Excessive Talking: Often talks excessively in social or professional settings.
   7. Blurts Out Answers: Often blurts out an answer before a question has been fully completed; finishes sentences.
   8. Difficulty Waiting Turn: Often has profound difficulty waiting their turn (in line, in traffic, in conversation).
   9. Interrupts / Intrudes: Often interrupts or intrudes on others (butts into conversations, games, or meetings).

The Five Essential Diagnostic Stipulations

To confirm a valid ADHD diagnosis, the patient must fulfill all five DSM-5 stipulations:

1. Symptom Threshold: Meets symptom criteria in Inattention, Hyperactivity/Impulsivity, or both for at least 6 months.
2. Age of Onset Prior to 12 Years: Several inattentive or hyperactive-impulsive symptoms must have been present prior to age 12 years. In adult evaluations, this requires retrospective collateral confirmation via childhood school report cards or interviews with parents/older siblings.
3. Pervasiveness Across Multiple Settings: Several symptoms must be manifest in TWO OR MORE SETTINGS (e.g., at home AND at school/work; with friends/relatives; in extracurricular activities). A child who exhibits disruptive behavior strictly at home or strictly in one classroom does not have ADHD.
4. Functional Impairment: Clear evidence that symptoms significantly interfere with or reduce the quality of social, academic, or occupational functioning.
5. Alternative Etiology Exclusion: Symptoms do not occur exclusively during the course of schizophrenia or another psychotic disorder and are not better accounted for by another mental disorder (e.g., mood disorder, generalized anxiety disorder, PTSD, sleep apnea, or substance intoxication/withdrawal).

---

Clinical Presentations & The Adult Phenotype

ADHD manifests in three distinct presentations based on symptom distribution over the preceding 6 months:

1. Combined Presentation: Fulfills both Inattention AND Hyperactivity-Impulsivity criteria. Most common overall presentation in clinical practice.
2. Predominantly Inattentive Presentation: Fulfills Inattention criteria, but falls short of Hyperactivity-Impulsivity thresholds. Historically underdiagnosed, especially in females. Girls with inattentive ADHD present as quiet, daydreaming, disorganized, and easily fatigued, frequently mislabeled as anxious or unmotivated until academic demands overwhelm executive functioning in high school or college.
3. Predominantly Hyperactive/Impulsive Presentation: Fulfills Hyperactivity-Impulsivity criteria without significant inattentive deficits. Most common in preschool and early elementary school boys; least common in adults.

The Metamorphosis of Adult ADHD

As individuals mature, overt motor hyperactivity (running, climbing, jumping) typically attenuates due to fronto-striatal maturation. However, the core neurobiological deficit shifts into distinct adult phenotypes:

                    PEDIATRIC VS. ADULT ADHD MANIFESTATIONS

   Pediatric Manifestation             Adult Manifestation & Real-World Complication
   ═════════════════════════════════════════════════════════════════════════════════════════════════════════════
   Running around, leaving seat        Internal subjective restlessness; inability to relax; fidgeting with
                                       pens/phones; overbooking schedule; intolerance of quiet environments.
   ─────────────────────────────────────────────────────────────────────────────────────────────────────────
   Blurting out answers in class       Interrupting colleagues; conversational impatience; impulsive career
                                       resignations; explosive road rage; impulsive online shopping.
   ─────────────────────────────────────────────────────────────────────────────────────────────────────────
   Disorganized backpack / lost toys   Chronic procrastination; severe time blindness; chronic lateness;
                                       unpaid bills; tax delinquency; messy home/desk; missed project deadlines.
   ─────────────────────────────────────────────────────────────────────────────────────────────────────────
   Temper tantrums / fighting          Emotional dysregulation; rejection sensitive dysphoria (RSD); low
                                       frustration tolerance; rapid emotional lability; marital discord.
   ═════════════════════════════════════════════════════════════════════════════════════════════════════════════

---

Standardized Rating Scales & Diagnostic Workup

An accurate ADHD diagnosis requires systematic multi-informant documentation utilizing validated rating instruments:

• Pediatric Scales (Ages 6 to 12 Years):
  • Vanderbilt ADHD Diagnostic Rating Scales: The gold standard in primary care. Includes validated Parent and Teacher forms. Assesses all 18 DSM symptoms alongside validated comorbidity screening subscales for Oppositional Defiant Disorder (ODD), Conduct Disorder (CD), and anxiety/depression. Both parent and teacher forms must demonstrate cross-setting impairment.
  • Conners 3 Rating Scales: Comprehensive multi-informant scales covering ages 6 to 18 years.
• Adult Rating Scales:
  • Adult ADHD Self-Report Scale (ASRS v1.1): Developed with the World Health Organization; features a highly validated 6-item screening tool and a full 18-item symptom checklist.
• Objective Diagnostic Testing Trap: Computerized Continuous Performance Tests (CPTs, e.g., TOVA, QbTest) and neuroimaging are NOT recommended or required for clinical diagnosis by the AAP or AACAP, as they suffer from poor sensitivity and specificity.

---

AAP Stepwise Management Algorithm by Age Group

The American Academy of Pediatrics (AAP) 2019 Clinical Practice Guideline delineates a rigorous, age-stratified management pathway:

                    AAP STEPWISE ADHD TREATMENT BY AGE GROUP

   Age Group               First-Line Intervention                   Second-Line / Adjunctive Options
   ═════════════════════════════════════════════════════════════════════════════════════════════════════════════
   Preschool-Aged          EVIDENCE-BASED PARENT TRAINING            Methylphenidate pharmacotherapy
   Children (Ages 4-5)     IN BEHAVIOR MANAGEMENT (PTBM)             ONLY IF behavioral therapy fails and
                           and classroom behavioral interventions.   moderate-to-severe dysfunction persists.
   ─────────────────────────────────────────────────────────────────────────────────────────────────────────
   School-Aged Children    FDA-APPROVED MEDICATIONS                  Behavioral classroom interventions;
   (Ages 6-11)             COMBINED WITH PTBM and educational        IEP under IDEA or 504 Plan accommodations;
                           accommodations (IEP / 504 Plan).          non-stimulant alternatives.
   ─────────────────────────────────────────────────────────────────────────────────────────────────────────
   Adolescents             FDA-APPROVED MEDICATIONS with             Behavioral therapies, executive skills
   (Ages 12-18)            adolescent assent, COMBINED WITH          coaching, 504 Plan with extended time;
                           educational accommodations.               substance risk mitigation.
   ═════════════════════════════════════════════════════════════════════════════════════════════════════════════

Educational Accommodations: 504 Plans vs. IEPs

Primary care physicians frequently write medical necessity letters for academic accommodations:

• Section 504 Plan (Rehabilitation Act): Provides civil-rights accommodations for physical or mental impairments that substantially limit major life activities. Common accommodations include: extended time on examinations (1.5x to 2x), preferential seating at the front of the classroom away from doors/windows, quiet testing environments, chunking long assignments into smaller milestones, and permission to take scheduled movement breaks.
• Individualized Education Program (IEP; IDEA Act): Required when the student requires specialized, modified educational instruction and specialized learning goals beyond simple classroom accommodations.

---

First-Line Pharmacotherapy: Stimulant Medications

Stimulants represent the most effective pharmacotherapeutic class in psychiatric medicine, demonstrating clinical response rates of 70% to 80% (compared to 40% to 50% for non-stimulants). If a patient fails to respond to one stimulant class, there is a 50% likelihood of robust response to the alternative class; systematic trialing of both classes yields an overall response rate exceeding 85% to 90%.

                       STIMULANT PHARMACOLOGY & FORMULATIONS

   Stimulant Class       Mechanism of Action           Formulations & Brand Names    Clinical Pearls
   ═════════════════════════════════════════════════════════════════════════════════════════════════════════════
   Methylphenidate-      Selectively blocks DAT & NET  • Short-Acting: Ritalin,      Preferred first-line in
   Based Formulations    transporters, preventing      Focalin (dexmethylphenidate)  children and adolescents;
                         catecholamine reuptake.       • Long-Acting: Concerta       better side-effect profile;
                         Does not promote release.     (OROS), Focalin XR, Aptensio, transdermal patch (Daytrana)
                                                       Daytrana patch, Cotempla.     available for swallowing issues.
   ─────────────────────────────────────────────────────────────────────────────────────────────────────────
   Amphetamine-          Blocks DAT & NET reuptake     • Short-Acting: Adderall,     Often preferred in adults;
   Based Formulations    AND promotes reverse-transport Dexedrine, Zenzedi           more potent catecholamine
                         vesicular catecholamine       • Long-Acting: Adderall XR,   release; Lisdexamfetamine
                         release into synaptic cleft.  Vyvanse (lisdexamfetamine),   has lowest diversion risk
                                                       Mydayis, Dynavel, Adzenys.    due to prodrug cleavage.
   ═════════════════════════════════════════════════════════════════════════════════════════════════════════════

The Lisdexamfetamine Prodrug Mechanism

Lisdexamfetamine (Vyvanse) is an inactive prodrug in which d-amphetamine is covalently bonded to the essential amino acid L-lysine. Following oral ingestion, it is absorbed intact from the gastrointestinal tract into the portal circulation. Enzymatic hydrolysis by aminopeptidases on the surface of red blood cells cleaves the peptide bond, gradually liberating free active d-amphetamine.

• Pharmacokinetic Benefit: Provides smooth, predictable 12- to 14-hour therapeutic coverage without sharp plasma peaks and valleys.
• Tamper Resistance & Diversion Mitigation: Because therapeutic activation requires systemic enzymatic cleavage by red blood cells, snorting (intranasal) or intravenous injection yields no rapid euphoric high, dramatically reducing illicit abuse and diversion potential on college campuses.

Formulations: Prioritizing Long-Acting Agents

Extended-release (long-acting) formulations are strongly preferred over immediate-release agents for routine chronic management:

1. Eliminates the need for midday administration by the school nurse, removing social stigma and medication theft.
2. Provides smooth, all-day coverage encompassing homework, after-school activities, and evening family interactions.
3. Prevents sharp rebound behavioral crashes and emotional irritability when short-acting levels plummet.
4. Significantly blunts the reinforcing euphoria associated with rapid plasma peaks, minimizing addiction and street diversion.

Stimulant Adverse Effects & Actionable Clinical Management

                   STIMULANT ADVERSE EFFECTS & CLINICAL MITIGATION

   Adverse Reaction          Incidence & Pathophysiology              Actionable Clinical Management Strategy
   ═════════════════════════════════════════════════════════════════════════════════════════════════════════════
   Appetite Suppression     Affects 50-60% of patients; central      • Administer medication DURING or AFTER a large,
   and Weight Loss           hypothalamic appetite suppression.       nutrient-dense breakfast.
                                                                      • Provide calorie-dense evening dinners and
                                                                        bedtime snacks when stimulant wears off.
                                                                      • Liquid nutritional supplements (shakes).
   ─────────────────────────────────────────────────────────────────────────────────────────────────────────
   Growth Velocity           Transient reduction in height velocity   • Monitor height and weight on CDC growth charts
   Attenuation               (~1-2 cm over 1-3 years); adult height    at EVERY visit.
                             is minimally affected.                   • Consider planned "drug holidays" on weekends
                                                                        or summer breaks if severe growth failure.
   ─────────────────────────────────────────────────────────────────────────────────────────────────────────
   Sleep-Onset Insomnia      Delayed sleep latency from evening       • Ensure extended-release taken early in morning.
                             stimulant receptor occupancy.            • Strict sleep hygiene (remove screens/devices).
                                                                      • Add evening low-dose Guanfacine or Clonidine.
   ─────────────────────────────────────────────────────────────────────────────────────────────────────────
   Afternoon Rebound         Rebound irritability, tantrums, or       • Transition to longer-acting formulation;
   Dysphoria / Irritability  hyperactivity as drug clears.            • Add a tiny "booster" dose of short-acting
                                                                        stimulant (e.g., 2.5-5 mg) in late afternoon.
   ─────────────────────────────────────────────────────────────────────────────────────────────────────────
   Mild Vital Sign Changes   Mean increase in HR (3-6 bpm) and        • Monitor vitals at every visit;
                             BP (2-4 mmHg systolic/diastolic).        • Discontinue or add alpha-2 agonist if severe.
   ═════════════════════════════════════════════════════════════════════════════════════════════════════════════

Cardiovascular Safety & The Baseline ECG Question

A perennial board-examination question addresses pre-treatment cardiovascular screening in ADHD:

• The Consensus Guideline (AAP / AHA / ACC): A routine baseline 12-lead electrocardiogram (ECG) is NOT REQUIRED in asymptomatic children with an unremarkable personal and family cardiac history and a completely normal physical examination.
• Mandatory Pre-Treatment Cardiac History Screen (Red Flags):
  1. History of exertional syncope, presyncope, exertional chest pain, or excessive exertional dyspnea.
  2. History of pathologic cardiac murmurs, arrhythmias, or hypertension.
  3. Family history of sudden, unexplained cardiac death in family members younger than 40 years.
  4. Family history of hypertrophic cardiomyopathy (HCM), Long QT syndrome, Brugada syndrome, arrhythmogenic right ventricular cardiomyopathy (ARVC), or Wolff-Parkinson-White (WPW) syndrome.
• Actionable Rule: If any cardiac red flag is identified in personal or family history, stimulant initiation must be deferred pending pediatric cardiology clearance, 12-lead ECG, and echocardiography.

---

Non-Stimulant Medications: Atomoxetine & Alpha-2 Agonists

Non-stimulant medications are indicated when stimulants produce intolerable side effects (severe anorexia, unmanageable insomnia, severe motor tics), when active substance use disorders create unacceptable diversion risks, or as adjunctive therapy for refractory symptoms.

                     NON-STIMULANT PHARMACOTHERAPY FOR ADHD

   Medication     Mechanism & Dosing                Clinical Pearls & Niches     Adverse Effects & Black Box Warnings
   ═════════════════════════════════════════════════════════════════════════════════════════════════════════════
   Atomoxetine    Selective Norepinephrine          • Non-controlled substance;  • DELAYED ONSET: Requires 4 to 6
   (Strattera)    Reuptake Inhibitor (NRI).           zero abuse liability.        WEEKS for full therapeutic efficacy.
                  Start 0.5 mg/kg/day, titrate to   • Excellent for comorbid     • BLACK BOX WARNING: Increased suicidal
                  target 1.2-1.4 mg/kg/day (max       anxiety or substance abuse.  ideation in children/young adults.
                  100 mg daily). Once/twice daily.  • Smooth 24-hr coverage.     • Nausea, fatigue; rare hepatotoxicity.
   ─────────────────────────────────────────────────────────────────────────────────────────────────────────
   Guanfacine ER  Selective postsynaptic            • Excellent for comorbid     • Sedation, somnolence, dizziness,
   (Intuniv)      alpha-2A adrenergic receptor        tics/Tourette syndrome,      bradycardia, orthostatic hypotension.
                  agonist in prefrontal cortex.       ODD, impulsivity, insomnia.• CRITICAL WARNING: NEVER STOP
                  Dose: 1 to 4 mg once daily          Can be monotherapy or        ABRUPTLY! Taper slowly to prevent
                  in the evening.                     adjunctive to stimulants.    life-threatening REBOUND HYPERTENSION.
   ─────────────────────────────────────────────────────────────────────────────────────────────────────────
   Clonidine ER   Non-selective alpha-2 adrenergic  • Potent sedative; excellent • Significantly more sedating and
   (Kapvay)       agonist (alpha-2A, 2B, 2C).         for severe hyperactivity,    hypotensive than guanfacine.
                  Dose: 0.1 to 0.4 mg once daily      severe aggression, insomnia.• Rebound hypertension risk on abrupt
                  at bedtime (or divided BID).      • High efficacy in tics.       discontinuation.
   ─────────────────────────────────────────────────────────────────────────────────────────────────────────
   Viloxazine ER  Selective Norepinephrine          • Approved in pediatric &    • BLACK BOX WARNING: Suicidal ideation.
   (Qelbree)      Reuptake Inhibitor (NRI).           adult ADHD; non-controlled.• Strong CYP1A2 inhibitor (contra-
                  Dose: 100-400 mg once daily.      • Fast-acting non-stimulant.   indicated with theophylline, tizanidine).
   ═════════════════════════════════════════════════════════════════════════════════════════════════════════════

Atomoxetine: The Delayed-Onset Non-Stimulant

Atomoxetine selectively blocks the norepinephrine transporter (NET). Because NET clears both norepinephrine and dopamine in the prefrontal cortex, atomoxetine boosts both neurotransmitters in the PFC without increasing dopamine in the nucleus accumbens, resulting in zero euphoria and zero abuse liability (non-scheduled agent).

• The Critical Clinical Difference from Stimulants: While stimulants work immediately on the first day of administration, atomoxetine requires 4 to 6 weeks of continuous daily administration to achieve therapeutic efficacy. Clinicians must prepare families for this delayed onset to prevent premature drug abandonment.
• Safety Monitoring: The FDA issued a black box warning for increased suicidal thoughts in children and adolescents. Rare, severe idiosyncratic hepatotoxicity can occur; instruct patients to discontinue the drug and contact the clinic immediately for jaundice, dark urine, or unexplained right upper quadrant tenderness.

Alpha-2 Agonists: Guanfacine ER and Clonidine ER

Centrally acting alpha-2 agonists directly stimulate postsynaptic $\alpha_{2A}$ receptors in the prefrontal cortex, mimicking endogenous norepinephrine and strengthening prefrontal network connectivity. They are uniquely effective for patients with ADHD and comorbid tic disorders (Tourette syndrome), oppositional defiant disorder (ODD), physical aggression, or stimulant-induced insomnia.

• Selectivity: Guanfacine is 15- to 20-fold more selective for $\alpha_{2A}$ receptors than clonidine, producing far less sedation and hypotension.
• The Board-Style Critical Red Flag: Rebound Hypertensive Crisis:
  • Centrally acting alpha-2 agonists suppress sympathetic outflow from the vasomotor center in the brainstem.
  • Abrupt cessation triggers a massive, life-threatening sympathoadrenal rebound surge with profound hypertension, tachycardia, severe headache, tremors, diaphoresis, and risk of hypertensive encephalopathy or stroke.
  • Mandatory Tapering Protocol: When discontinuing guanfacine or clonidine, the dose MUST BE TAPERED SLOWLY (e.g., reducing guanfacine by no more than 1 mg every 3 to 7 days; clonidine by 0.1 mg every 3 to 7 days).

---

Controlled Substance Stewardship & Regulatory Management

Because stimulants are DEA Schedule II controlled substances, family physicians must balance compassionate, effective clinical care with rigorous medico-legal stewardship to prevent misuse and diversion:

1. Prescription Drug Monitoring Program (PDMP): Mandatorily check the state PDMP database prior to the initial prescription and periodically at every follow-up visit to verify adherence, identify multi-provider prescribing, and detect co-prescribed sedatives or opioids.
2. Controlled Substance Treatment Agreement: Execute a signed formal treatment agreement detailing prescription boundaries: medications taken strictly as prescribed, no early refills under any circumstances for 'lost' or 'stolen' pills, single-prescriber and single-pharmacy rules, and mandatory agreement to submit to random urine drug screening.
3. Urine Drug Testing (UDT/UDS): Perform baseline and random periodic urine drug screens. Verify two distinct findings: (1) the presence of the prescribed stimulant (confirming patient adherence), and (2) the absence of illicit substances (cocaine, unprescribed amphetamines, non-prescribed opioids, benzodiazepines).
4. Routine Monitoring Schedule: Stable patients maintained on stimulants require clinical reassessment at least every 3 to 6 months to monitor resting blood pressure, pulse, weight, growth velocity, rating scales, and medication compliance.